HER2-positive Gastric Cancer Clinical Trials

43 clinical trials for HER2-positive Gastric Cancer across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer — RECRUITING · PHASE3
• A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer — RECRUITING · PHASE3
• Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer — RECRUITING · PHASE1
• HER-2 B Cell Peptide Vaccine — RECRUITING · PHASE1
• Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China — RECRUITING
• First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) — RECRUITING · PHASE2
• Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma — RECRUITING · PHASE2
• Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens — RECRUITING · PHASE1
• Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease — RECRUITING · PHASE2
• Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study — NOT_YET_RECRUITING · PHASE2
• A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 — TERMINATED · PHASE1
• 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study — COMPLETED · NA
• A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer — NOT_YET_RECRUITING · PHASE2
• ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer — COMPLETED · PHASE2
• TAC T-cells for the Treatment of HER2-positive Solid Tumors — TERMINATED · PHASE1
• JSKN003 Combined Treatment of HER2-positive Gastric Cancer — NOT_YET_RECRUITING · PHASE2
• First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors — OTHER · PHASE1
• BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors — TERMINATED · PHASE1
• ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors — COMPLETED · PHASE1
• RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer — NOT_YET_RECRUITING · PHASE2
• Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC — NOT_YET_RECRUITING · PHASE2
• PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors — COMPLETED · PHASE1
• PRS-343 in HER2-Positive Solid Tumors — COMPLETED · PHASE1
• ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer — WITHDRAWN · PHASE1
• Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC — OTHER · PHASE1
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene — COMPLETED · PHASE1
• Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors — SUSPENDED · PHASE1
• [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors — OTHER · PHASE2
• Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers — TERMINATED · PHASE1
• Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma — COMPLETED · PHASE2
• RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer — OTHER · PHASE2
• Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer — OTHER · PHASE2
• Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial — OTHER · PHASE2
• Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System — OTHER
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors — COMPLETED · PHASE1
• Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer — OTHER · PHASE2
• Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients — COMPLETED
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers — WITHDRAWN · PHASE1
• ctDNA Screening in Advanced HER2 Positive Gastric Cancer — OTHER
• Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer — OTHER · PHASE1

Refine this search